Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARCOME 13 / OS2016
2024-514780-26-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jul 2024
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mifamurtide in osteosarcoma (OS) (2 arms), sponsored by Unicancer. Primary endpoint: Event-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
mifamurtide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2024-514780-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514780-26-00.